Skip to main content

MeMed Licenses Test to DiaSorin to Distinguish Viral, Bacterial Infections

NEW YORK – Infectious disease testing firm MeMed and diagnostics company DiaSorin announced on Tuesday a licensing agreement giving DiaSorin the right to commercialize MeMed's BV test for distinguishing between bacterial and viral infections.

Under the agreement, Saluggia, Italy-based DiaSorin will commercialize the test for use on its Liaison analyzer platform, which will make it available on the more than 5,000 LIASON systems installed globally.

Haifa, Israel-based MeMed will also continue to sell the test for use on its own point-of-care platform, the MeMed Key.

Additional terms of the agreement were not disclosed.

"This partnership will fast-track access to MeMed BV, helping clinicians to better manage patients and potentially leading to better outcomes and cost savings for the healthcare system," MeMed CEO and Cofounder Eran Eden, said in a statement. "It is also well aligned with our commercial strategy, complementing our direct sales approach via our platform MeMed Key. We look forward to working closely with the DiaSorin team to help improve patient outcomes worldwide."

"This is an absolute breakthrough from a clinical standpoint, also considering the importance of reaching the most accurate and informed decisions for our patients during these difficult times,” said DiaSorin CEO Carlo Rosa. "We are excited to have the chance to incorporate a new, cutting-edge test in our menu, making this new innovative technology available to our customers worldwide."